US Patent 3,962,432: Scope, Claim Analysis, Expiration, and Pamidronate Patent Landscape

US Patent 3,962,432 is the foundational U.S. patent covering aminoalkane-diphosphonic acids, including 3-amino-1-hydroxypropane-1,1-diphosphonic acid, now known as pamidronic acid. It covers therapeutic use, pharmaceutical compositions, concentration ranges, alkali-metal salts, and oral excipients. The patent was issued on June 8, 1976, and its ordinary 17-year term expired on June 8, 1993. It no longer creates an enforceable U.S. patent barrier to pamidronate development, manufacturing, or marketing.

The patent remains commercially relevant as prior art and as the historical basis for pamidronate’s early intellectual-property position. It does not provide current exclusivity. Pamidronate is a small-molecule bisphosphonate, so biosimilar rules do not apply.

What drug and active ingredient does US Patent 3,962,432 protect?

The principal compound identified by the claims is 3-amino-1-hydroxypropane-1,1-diphosphonic acid, commonly called:

Name	Description
Pamidronic acid	Free-acid form
Pamidronate	General nonproprietary name
Pamidronate disodium	Water-soluble disodium salt used in injectable products
ATC classification	M05BA03
Drug class	Bisphosphonate
Original branded product	Aredia
Original innovator	Ciba-Geigy, later Novartis

Pamidronate inhibits osteoclast-mediated bone resorption. The patented therapeutic concept was the use of aminoalkane-diphosphonic acids to treat abnormal deposition or dissolution of poorly soluble calcium salts.

The claim text supplied in the question omits the chemical drawings represented by “EQU5,” “EQU6,” and “EQU7.” The written claims identify the relevant genus as aminoalkane-diphosphonic acids in which R1 and R2 are hydrogen or C1-C3 alkyl groups. Claim 2 and the corresponding dependent composition claims specifically identify pamidronic acid and its water-soluble salts.

When did US Patent 3,962,432 expire?

US Patent 3,962,432 issued June 8, 1976. Because it predates the 1995 U.S. patent-term transition, its ordinary term was 17 years from grant under the then-applicable patent statute. The patent therefore expired June 8, 1993, absent an unusual patent-term adjustment or extension.

Event	Date or status
U.S. patent number	3,962,432
Issue date	June 8, 1976
Ordinary term	17 years from issuance
Expiration	June 8, 1993
Current enforceability	Expired
Patent-term restoration	No relevant restoration identified for this patent
Current blocking effect	None

The Hatch-Waxman patent-term-extension regime was enacted after this patent issued. The patent’s expiration predates the modern Orange Book patent-certification disputes involving pamidronate products.

What does claim 1 cover?

Claim 1 is a method-of-treatment claim. It covers administering an aminoalkane-diphosphonic acid or a pharmacologically acceptable water-soluble salt to a warm-blooded animal with a condition caused by abnormal deposition or dissolution of difficultly soluble calcium salts.

The claim has several limiting elements:

A therapeutic condition involving abnormal calcium-salt deposition or dissolution.
A warm-blooded animal.
Oral or parenteral administration.
A dose of 0.05 to 500 mg/kg of body weight.
An aminoalkane-diphosphonic acid within the specified Markush group or a pharmacologically acceptable water-soluble salt.
Administration as tablets, pills, capsules, or injectable solutions.

The claim is broader than pamidronate alone. It covers the defined genus of aminoalkane-diphosphonic acids and their qualifying water-soluble salts. Claim 2 narrows the scope to pamidronic acid and its water-soluble salts.

The disease language is functional and broad. It is directed to pathological or physiological conditions involving calcium salts rather than to one named disease. Potential historical indications include hypercalcemia of malignancy, osteolytic lesions associated with multiple myeloma, and osteolytic lesions associated with breast cancer.

Because claim 1 is expired, its breadth has no current exclusionary effect. Its importance is historical: it shows that the early patent position covered the active ingredient class, not merely one branded formulation.

What do claims 3 through 8 cover?

Claims 3 through 8 cover pharmaceutical compositions rather than treatment methods.

Claim	Main subject matter	Scope
3	Pharmaceutical composition	Aminoalkane-diphosphonic acid or water-soluble salt plus a major amount of pharmaceutically acceptable excipients
4	Narrowed composition	Pamidronic acid or a water-soluble salt
5	Quantified composition	0.01% to 5% by weight active ingredient, remainder excipients
6	Narrowed quantified composition	Pamidronic acid or a water-soluble salt
7	Salt limitation	Alkali-metal salt
8	Excipient limitation	Orally acceptable excipient

Claim 3: composition with excipients

Claim 3 requires an effective amount of the covered diphosphonic-acid derivative and a major amount of pharmaceutically acceptable excipients. The phrase “consisting essentially of” limits the composition to the listed active ingredient and excipient system, while allowing components that do not materially alter the claimed characteristics.

The claim could historically have reached tablets, capsules, injectable compositions, and other pharmaceutical presentations containing a qualifying active ingredient.

Claim 5: concentration range

Claim 5 requires 0.01% to 5% by weight of the active derivative. This is a formulation-range claim. It is broader than a single commercial concentration but narrower than any composition containing the active ingredient at any concentration.

The claim does not require a specific excipient, pH, container, preservative, sterility condition, particle size, or manufacturing process.

Claim 7: alkali-metal salts

Claim 7 narrows claim 5 to alkali-metal salts. Pamidronate disodium is the commercially important example. The claim does not appear limited to disodium pamidronate alone; depending on the underlying chemical formula and claim construction, it could encompass other pharmacologically acceptable alkali-metal salts within the claimed genus.

Claim 8: oral excipients

Claim 8 narrows the composition to one having an orally acceptable excipient. It is directed to oral dosage forms rather than injectable products.

How broad is the patent’s chemical scope?

The patent has two layers of chemical coverage.

First, claims 1, 3, and 5 cover a genus of aminoalkane-diphosphonic acids in which the defined substituents R1 and R2 may be hydrogen or lower alkyl groups. Second, claims 2, 4, and 6 focus on 3-amino-1-hydroxypropane-1,1-diphosphonic acid, the pamidronate structure.

The practical commercial center of gravity is pamidronate disodium. The patent’s broader genus could include related amino-bisphosphonates if their structures fall within the actual formula shown in the issued patent. It should not be assumed that every bisphosphonate, every amino-bisphosphonate, or every substituted phosphonate falls within the claims. Exact chemical mapping requires the original structural drawings and the complete specification.

The claims do not expressly cover:

Zoledronic acid as a general class claim.
Alendronate unless its structure falls within the specified formula.
Risedronate as a general class claim.
Ibandronate as a general class claim.
Non-pharmaceutical industrial uses.
Specific manufacturing processes.
Specific container-closure systems.
Specific sterile manufacturing controls.
Particular infusion rates or premedication regimens.

What FDA products and indications are associated with pamidronate?

The FDA approved Aredia, pamidronate disodium injection, for treatment of hypercalcemia of malignancy and osteolytic lesions associated with multiple myeloma and breast cancer. The original product was administered intravenously, with dosing dependent on indication and serum calcium or disease status. FDA labeling describes pamidronate as a bone-resorption inhibitor and provides dosing regimens substantially below the patent’s broad upper boundary of 500 mg/kg for ordinary clinical use.[2]

Pamidronate is also marketed in the United States through abbreviated new drug applications as an injectable generic. The product is a conventional small-molecule generic, not a biosimilar.

Regulatory issue	Status
FDA pathway	NDA for Aredia; ANDA pathway for generic pamidronate injection
Dosage form	Intravenous injection or infusion
Active ingredient	Pamidronate disodium
Biologic status	Not a biologic
Biosimilar pathway	Not applicable
Reference product	Aredia
Current market structure	Generic injectable competition
Key clinical uses	Hypercalcemia of malignancy; osteolytic lesions

What is the Orange Book status of pamidronate?

The original 1976 patent is far beyond the period during which it could be listed as an unexpired Orange Book patent. Any historical listing associated with Aredia would have expired decades ago.

Orange Book relevance for pamidronate today is limited to identifying the reference product, approved dosage form, active ingredient, and any remaining listed patents or exclusivity entries. The expired US 3,962,432 patent cannot support a current Paragraph IV litigation strategy.

For an ANDA applicant, an expired patent generally does not require a Paragraph IV certification directed to that patent. Current certifications depend on patents listed against the relevant reference product and their legal status, not on every historical patent that once covered the active ingredient.

When did pamidronate lose market exclusivity?

Pamidronate’s primary composition and therapeutic-use exclusivity ended long before the current generic market matured.

Exclusivity category	Pamidronate position
US 3,962,432 patent	Expired June 8, 1993
Small-molecule data exclusivity	Expired many years ago
Orphan-drug exclusivity	No current relevant exclusivity
Pediatric exclusivity	No current relevant exclusivity
Formulation exclusivity	Any historical rights are expired or product-specific
Biosimilar exclusivity	Not applicable
Current patent barrier from US 3,962,432	None

Aredia was approved in the early 1990s, and generic pamidronate products subsequently entered after the relevant product and patent protections ceased to block ANDA approval. The commercial product has been exposed to generic competition for many years.

Which patents protect pamidronate formulations?

US 3,962,432 is not a modern formulation patent in the narrow sense. It claims broad pharmaceutical compositions containing the active ingredient or a covered salt, including compositions with 0.01% to 5% active ingredient.

It does not recite the formulation details that usually define later-generation injectable patents, such as:

A defined pH range.
A specific buffer system.
A specified calcium or phosphate impurity limit.
A particular concentration of pamidronate disodium.
A defined infusion volume.
A terminal sterilization process.
A specific vial or bag configuration.
A stability period under defined storage conditions.

Any later formulation patent would require separate analysis by patent number, claims, priority date, and Orange Book listing. The claims supplied do not establish protection for a later proprietary formulation, improved stability profile, or manufacturing process.

Are there Paragraph IV challenges or pamidronate patent lawsuits?

US 3,962,432 could not support a current Paragraph IV challenge because it expired in 1993. A Paragraph IV certification is directed to a listed patent that is asserted to be invalid, unenforceable, or not infringed. An expired patent no longer creates a patent-based delay to ANDA approval.

The economically relevant litigation risk for pamidronate is therefore low. A generic applicant’s potential disputes would more likely concern:

A later-listed formulation patent.
A product-specific patent covering a device or presentation.
Patent ownership or license issues.
ANDA product quality, bioequivalence, or manufacturing disputes.
Regulatory enforcement unrelated to the expired foundational patent.

No current enforceable claim can be asserted under US 3,962,432 against a pamidronate manufacturer.

How does the pamidronate patent estate compare with competing bisphosphonates?

Product	Active ingredient	Drug type	Foundational patent position	Current biosimilar risk
Aredia	Pamidronate disodium	Small molecule	Foundational patent expired	None; generic risk applies
Zometa	Zoledronic acid	Small molecule	Separate compound and use patents	None; generic risk applies
Fosamax	Alendronate	Small molecule	Separate compound and use patents	None; generic risk applies
Actonel	Risedronate	Small molecule	Separate compound and use patents	None; generic risk applies
Boniva	Ibandronate	Small molecule	Separate compound and use patents	None; generic risk applies
Prolia	Denosumab	Biologic monoclonal antibody	Biologic patent estate	Biosimilar risk applies

Pamidronate’s estate is weaker than a recently launched small-molecule product because its core compound, method, and composition claims expired decades ago. It also lacks the biologic exclusivity and manufacturing complexity associated with denosumab.

What generic entry risks exist for pamidronate?

Generic entry risk is established rather than prospective. Pamidronate is an off-patent injectable bisphosphonate with multiple generic-market participants or historical generic suppliers.

The principal barriers are operational and regulatory:

Sterile injectable manufacturing.
Compliance with current good manufacturing practice requirements.
Demonstration of pharmaceutical equivalence and bioequivalence under the applicable FDA framework.
Control of particulate matter, sterility, endotoxin, container integrity, and extractables.
Hospital contracting and supply reliability.
Competition from zoledronic acid and other bone-resorption therapies.

The patent does not create a current barrier to any of these activities.

What licensing deals affect the patent?

The historical commercialization of Aredia involved the originator’s corporate succession from Ciba-Geigy to Novartis. That corporate history does not extend the patent term and does not preserve an enforceable monopoly under US 3,962,432.

No license can revive an expired patent. A private license could still allocate know-how, trademarks, regulatory materials, manufacturing rights, or confidential technology, but those contractual rights would be distinct from the expired patent claims.

How strong is the patent estate for pamidronate?

The estate is historically broad but commercially exhausted.

Strength factor	Assessment
Core active-ingredient coverage	Historically broad
Pamidronate-specific coverage	Expressly included
Method-of-use coverage	Broad but expired
Composition coverage	Broad but expired
Concentration coverage	0.01% to 5%, expired
Salt coverage	Includes pharmacologically acceptable water-soluble salts; alkali-metal limitation in claim 7
Formulation specificity	Limited
Manufacturing coverage	Not established by the supplied claims
Current enforceability	None
Generic vulnerability	Very high
Biosimilar vulnerability	Not applicable

Key Takeaways

US Patent 3,962,432 covers aminoalkane-diphosphonic acids, including pamidronic acid and pamidronate salts.
Claims 1 and 2 are method-of-treatment claims.
Claims 3 through 8 cover pharmaceutical compositions, concentration ranges, salts, and oral excipients.
The patent issued June 8, 1976, and expired June 8, 1993.
The patent cannot block current pamidronate development, manufacturing, or marketing.
Pamidronate is a small molecule, so biosimilar rules do not apply.
Current competitive risk comes from generic injectable products and alternative bisphosphonates, not from US 3,962,432.
Any current freedom-to-operate review must focus on later formulation, process, device, and product-specific patents rather than the expired foundational patent.

FAQs About US Patent 3,962,432 and Pamidronate

Does US Patent 3,962,432 cover pamidronate disodium?

Yes. Claims 2, 4, and 6 specifically cover 3-amino-1-hydroxypropane-1,1-diphosphonic acid and its pharmacologically acceptable water-soluble salts. Pamidronate disodium is the principal commercial salt.

Can a company launch generic pamidronate based on expiration of this patent?

The expiration of US 3,962,432 removes its patent barrier. A company must still obtain FDA approval and satisfy sterile injectable manufacturing, quality, labeling, and bioequivalence requirements.

Does the patent cover zoledronic acid?

No conclusion follows from the supplied claim text alone. Zoledronic acid has a different chemical structure and was protected through a separate patent estate. It should not be treated as covered merely because both products are bisphosphonates.

Is pamidronate eligible for a biosimilar application?

No. Pamidronate is a chemically synthesized small molecule. Generic approval proceeds through the ANDA framework rather than the biosimilar pathway.

Can an expired patent still affect pamidronate licensing?

It can have historical value in chain-of-title records, prior-art analysis, and diligence concerning old licenses. It cannot provide current exclusivity or support a patent-infringement claim.

References

United States Patent and Trademark Office. (1976). US Patent No. 3,962,432, Aminodiphosphonic acids and pharmaceutical compositions thereof.
U.S. Food and Drug Administration. (n.d.). Aredia (pamidronate disodium) injection prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
35 U.S.C. § 154. Patent term.
Novartis Pharmaceuticals Corporation. (n.d.). Aredia product information.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	2405254	Feb 4, 1974

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	332557	⤷ Start Trial
Austria	A76175	⤷ Start Trial
Belgium	822930	⤷ Start Trial
Canada	1033666	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 3,962,432

Summary for Patent: 3,962,432